{"database":"ENA","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Fastqsanger.gz":["ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR329/004/SRR32938604/SRR32938604.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR288/092/SRR28803792/SRR28803792_2.fastq.gz","ftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR288/092/SRR28803792/SRR28803792_1.fastq.gz"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Harvard Medical School"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA1104636"],"long_description":["In vivo CRISPR screens using activated CD8+ T cells have uncovered novel immunotherapy targets for cancer, yet similar high-throughput screens have not been performed using naive CD8+ T cells. Here we present an 899-gene in vivo CRISPR screen using naive CD8+ T cells, which identified the E3 ubiquitin ligase STUB1 as a novel negative regulator of anti-tumor CD8+ T cell responses. Stub1 knockout (KO) CD8+ T cells control tumor growth across multiple murine models. Mechanistically, STUB1 interacts with the adapter protein CHIC2 to regulate IL-27Ra expression in mouse and human CD8+ T cells. IL-27Ra expression is essential for the accumulation of Stub1 KO or Chic2 KO CD8+ T cells in tumors and tumor growth control. Together, these findings demonstrate that the STUB1-CHIC2 complex is a novel regulator of cytokine receptor expression in CD8+ T cells and provide the rationale for inhibiting this pathway to improve CD8+ T cell-mediated anti-tumor immunity."],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"","description":"A STUB1-CHIC2 complex decreases IL-27Ra expression on CD8+ T cells to restrain tumor immunity","dates":{"last_updated":"2025-05-03","first_public":"2025-05-03"},"accession":"PRJNA1104636","cross_references":{}}